Neurocrine Biosciences (NBIX) News Today $122.71 -0.95 (-0.77%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$122.30 -0.41 (-0.34%) As of 05/30/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 9,613 SharesMay 30 at 7:33 AM | insidertrades.comLansforsakringar Fondforvaltning AB publ Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 32,446 shares of the company'May 30 at 5:33 AM | marketbeat.comSiemens Fonds Invest GmbH Buys Shares of 6,225 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Siemens Fonds Invest GmbH bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 6,225 shares of the company's stock, valued at approximately $850May 30 at 5:14 AM | marketbeat.comPublic Employees Retirement System of Ohio Has $5.53 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Public Employees Retirement System of Ohio trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,518 shares ofMay 30 at 4:33 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Two Sigma Investments LPTwo Sigma Investments LP lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,771 shares of the company's stock afMay 30 at 3:54 AM | marketbeat.comDirector Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX)May 29 at 10:37 PM | gurufocus.comMackenzie Financial Corp Has $7.54 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mackenzie Financial Corp lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 36.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,221 shares of the company's stock after selling 31,362 shareMay 29 at 5:06 AM | marketbeat.comNeurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 LaunchedMay 29 at 12:57 AM | insidermonkey.comNxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28 at 8:25 PM | investing.comNxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28 at 7:43 PM | globenewswire.comNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28 at 4:18 PM | prnewswire.comGF Fund Management CO. LTD. Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GF Fund Management CO. LTD. purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 2,126 shares of the company's stock, valued at approximately $290,000. A number of otherMay 27, 2025 | marketbeat.comTidal Investments LLC Lowers Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tidal Investments LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 37.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,425 shares of the company's stock after selliMay 27, 2025 | marketbeat.comPeak Retirement Planning Inc. Purchases New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Peak Retirement Planning Inc. purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,630 shares of the company's stock, valueMay 26, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 19.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,070,0May 26, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Lowered by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,206 shares of the company's stock after selling 2May 26, 2025 | marketbeat.comCetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Cetera Investment Advisers raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 46.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,169 shares of the company's stoMay 25, 2025 | marketbeat.comNeurocrine Biosciences' SWOT analysis: stock's resilience amid market challengesMay 25, 2025 | investing.comProShare Advisors LLC Lowers Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)ProShare Advisors LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 54.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,532 shares of the company's stock after selling 11,206 sMay 24, 2025 | marketbeat.comInsider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0May 23, 2025 | benzinga.comWorldquant Millennium Advisors LLC Has $21.14 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Worldquant Millennium Advisors LLC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 44.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 154,852 shares of the company's stock after pMay 23, 2025 | marketbeat.comNuveen Asset Management LLC Sells 77,597 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Nuveen Asset Management LLC cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 267,980 shares of the company's stock after selling 77,597May 23, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 78.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,954 shares of thMay 22, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-two research firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating andMay 22, 2025 | marketbeat.com11,000 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Triglav Skladi D.O.O.Triglav Skladi D.O.O. purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,000 shares of the company's stock, valued at approximatMay 21, 2025 | marketbeat.comGotham Asset Management LLC Sells 9,603 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Gotham Asset Management LLC lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 62.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,714 sharesMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 140,744 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)D. E. Shaw & Co. Inc. reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 83.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,710 shares of the company's stock after selMay 21, 2025 | marketbeat.comTema Etfs LLC Invests $525,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tema Etfs LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 3,846 shares of the company's stock, valued at approximately $525,000. A number of otherMay 20, 2025 | marketbeat.comSiemens Fonds Invest GmbH Acquires New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Siemens Fonds Invest GmbH bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,225 shares of the company's stock, valued at approximatelyMay 20, 2025 | marketbeat.comSherbrooke Park Advisers LLC Has $399,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sherbrooke Park Advisers LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 45.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,921 shares of the company's stock after selling 2,May 20, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Holdings Lessened by Sarissa Capital Management LPSarissa Capital Management LP decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 309,116 shares of the companyMay 19, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Decreased by Rafferty Asset Management LLCRafferty Asset Management LLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,011 shares of the compMay 19, 2025 | marketbeat.comRaiffeisen Bank International AG Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Raiffeisen Bank International AG bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,400 shares of the company's stMay 19, 2025 | marketbeat.comMan Group plc Sells 151,015 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Man Group plc lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 51.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 145,164 shares of the companyMay 19, 2025 | marketbeat.comLazard Asset Management LLC Sells 15,643 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lazard Asset Management LLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,279May 17, 2025 | marketbeat.comNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual MeetingMay 16, 2025 | prnewswire.comNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive DyskinesiaMay 16, 2025 | prnewswire.comParkman Healthcare Partners LLC Sells 14,113 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Parkman Healthcare Partners LLC lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 115,727 shares of the company's stock aftMay 16, 2025 | marketbeat.comLighthouse Investment Partners LLC Makes New $2.05 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lighthouse Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,000 shares of the company's stock, valued aMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 456,979 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Jacobs Levy Equity Management Inc. lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 87.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,189 shaMay 16, 2025 | marketbeat.comFocus Partners Wealth Purchases 4,420 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Focus Partners Wealth boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,078 shares of the company's stock after acquiring anMay 16, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are BuyingMay 15, 2025 | insidermonkey.comNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITYâ„¢ (crinecerfont)May 15, 2025 | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Orbimed Advisors LLCOrbimed Advisors LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 210.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 938,120 shares of the company's stock aftMay 15, 2025 | marketbeat.comHudson Bay Capital Management LP Trims Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Hudson Bay Capital Management LP lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,342 shares of the company's stock after selling 9,658May 15, 2025 | marketbeat.comDeutsche Bank AG Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Deutsche Bank AG grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 461,782 shares of the company's stock after acquiring an additional 23,951 sharesMay 15, 2025 | marketbeat.comBank of America Corp DE Cuts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Bank of America Corp DE decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,034 shares of the companyMay 15, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside PotentialMay 15, 2025 | finance.yahoo.comNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal HyperplasiaMay 14, 2025 | prnewswire.comIntegral Health Asset Management LLC Invests $21.84 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Integral Health Asset Management LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 160,000 shares of the company'May 14, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.220.87▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼2116▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today Exelixis News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Halozyme Therapeutics News Today Repligen News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts